At the news
? NEUTRALIMPACT 2/10 144 filed Jun 5, 2026 at 16:32 ET
Director Gary Patou filed a Form 144 notice of intent to sell 1,322 shares of Xenon Pharmaceuticals common stock, valued at approximately $70,053 based on the filing date. This is a very small sale relative to the company's $5.1B market cap and appears to be a routine, low-conviction signal.
- Director Gary Patou filed Form 144 to sell 1,322 shares of XENE common stock.
- Estimated sale value is approximately $70,053 based on the filing date.
- The shares were acquired from restricted stock units vesting on 05/31/2026.
- The sale represents a tiny fraction of the company's $5.1B market cap.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access